- Home
- KLAC vs GILD Comparison
KLAC vs GILD Comparison
Compare KLAC & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLAC
- GILD
- Stock Information
- Founded
- KLAC 1975
- GILD 1987
- Country
- KLAC United States
- GILD United States
- Employees
- KLAC N/A
- GILD N/A
- Industry
- KLAC Electronic Components
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KLAC Technology
- GILD Health Care
- Exchange
- KLAC Nasdaq
- GILD Nasdaq
- Market Cap
- KLAC 101.6B
- GILD 119.7B
- IPO Year
- KLAC N/A
- GILD 1992
- Fundamental
- Price
- KLAC $754.30
- GILD $109.95
- Analyst Decision
- KLAC Buy
- GILD Buy
- Analyst Count
- KLAC 20
- GILD 27
- Target Price
- KLAC $836.35
- GILD $101.88
- AVG Volume (30 Days)
- KLAC 1.1M
- GILD 7.6M
- Earning Date
- KLAC 01-30-2025
- GILD 02-11-2025
- Dividend Yield
- KLAC 0.90%
- GILD 2.87%
- EPS Growth
- KLAC 20.61
- GILD N/A
- EPS
- KLAC 23.75
- GILD 0.38
- Revenue
- KLAC $10,846,957,000.00
- GILD $28,754,000,000.00
- Revenue This Year
- KLAC $23.47
- GILD $0.82
- Revenue Next Year
- KLAC $4.15
- GILD $3.21
- P/E Ratio
- KLAC $31.76
- GILD $289.34
- Revenue Growth
- KLAC 12.15
- GILD 6.04
- 52 Week Low
- KLAC $609.40
- GILD $62.07
- 52 Week High
- KLAC $896.32
- GILD $111.03
- Technical
- Relative Strength Index (RSI)
- KLAC 54.81
- GILD 75.82
- Support Level
- KLAC $737.94
- GILD $94.56
- Resistance Level
- KLAC $794.00
- GILD $106.69
- Average True Range (ATR)
- KLAC 21.24
- GILD 2.29
- MACD
- KLAC -1.39
- GILD 1.15
- Stochastic Oscillator
- KLAC 41.30
- GILD 93.47
About KLAC KLA Corporation
KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).